4.3.1 Sintesi e raccomandazioni - Biblioteca Medica

42. Roehrborn CG, van Kerrebroek P and Nordling J. Safety and efficacy of alfuzosin 10 mg
once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic
hyperplasia: a pooled analysis of three double-blind, placebo controlled studies. BJU
Intern, 2003: 92, 257-261
43. van Kerreboroeck P, Jardin A, Laval KU, van Cangh P and the ALFORTI Study Group.
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once
daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic
benign prostatic hyperplasia. Eur Urol, 2000: 37, 306-313
44. Höfner K, Claes H, De Reijke TM et al. Tamsulosin 0.4 mg once daily : effect on sexual
function in patients with lower urinary tract symptoms suggestive of benign prostatic
obstruction. Eur Urol, 1999: 36, 335-341
45. Lepor H for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled
study of tamsulosin in benign prostatic hyperplasia. Urology, 1998: 51, 892-900
46. Narayan P, Tewari A, for the United States 93-01 Study Group. A second phase III
multicenter placebo controlled study of 2 dosages of modified release tamsulosin iun
patients with symptoms of benign prostatic hyperplasia. J Urol, 1998: 160, 1701-
1706
47. Schulman CC, Cortvirend J, Jonas U, Lock TMTW, Vaage S, Speakman MJ on behalf of
the European Tamsulosin Study Group. Tamsulosin: 3-year long-term efficacy and
safety in patients with lower urinary tract symptoms suggestive of benign prostatic
obstruction: analysis of a European, Multinational, Multicenter, Open-label Study.
Eur Urol, 1999: 36, 609-620
48. Schulman CC, Lock TMTW, Buzelin IM et al. Long term use of tamsulosin to treat
lower urinary tract symptoms/benign prostatic hyperplasia. J Urol, 2001: 166, 1358-
1363
49. Mann RD, Biswas P, Freemantle S et al. The pharmacovigilance of tamsulosin: event data
on 12484 patients. BJU Intern, 2000: 85, 446-450
50. Lepor H for the Tamsulosin Investiogator Group. Long-term evaluation of tamsulosin in
benign prostatic hyperplasia: placebo-controlled, doubel-blind extension of phase III
trial. Urology, 1998: 51, 901-906
51. Wilt TJ, Mac Donald R, Rutks I. Tamsulosin for benign prostatic hyperplasia (Cochrane
Review). In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &
Sons, Ltd
52. Kirby RS, Andersen M, Gratzke P, Dahlstrand C and Høye K. A combined analysisi of
double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal
therapeutic system, doxazosin standard and placebo in patients with benign prostatic
hyperplasia. BJU Intern, 2001: 87, 192-200
53. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgreve HL, Albertsen
P, Roherborn CG, Nickel JC, Wang DZ, Taylor AM and Waldstreicher J for the
Finasteride Long-term Efficacy and Safety Study Group. The effect of finasteride on
the risk of acute urinary retention and the need for surgical treatment among men with
benign prostatic hyperplasia. N Engl J Med, 1998: 338, 557-563
248